Novel Prognostic Markers in Renal Cancer

Novel Prognostic Markers in Renal Cancer: a Protocol for the Analysis of Paraffin Embedded Tumour Samples

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01002937

Enrollment

182

Registered

2009-10-28

Start date

2008-12-01

Completion date

2014-12-17

Last updated

2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Cell Carcinoma

Keywords

Biomarkers, Prognosis response to treatment, Renal cancer

Brief summary

The purpose of this project is to analyze tumour tissue from a group of subjects with renal cell carcinoma, who have been treated at the Royal Marsden Hospital.

Detailed description

Renal cancers have different clinical outcomes. The principal research objective is to study tumour tissue from renal cancer patients and try and understand why some cancers progress more rapidly than others. Further, another key aim of this study is to try and understand why some patients respond to treatment and others do not.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* The presence of histologically proven renal cell cancer * The availability of paraffin embedded tissue * Informed consent needed for tissue taken after January 2006 (date of enforcement of human tissue act)

Exclusion criteria

* Absence of histological tissue * Absence of consent to study tissue after January 2006

Design outcomes

Primary

Measure	Time frame
The profiling of the expression of signal transduction biomarkers, gene expression, gene copy numbers and effect of mutations of the VHL gene in renal cancer and their relationship to clinical outcomes.	5 years

Countries

United Kingdom

Outcome results